EDMUND FREUND MD JOINS VIRATECH ADVISORY COMMITTEESTOCKTON, CALIFORNIA/Date, 2012 /Globe Newswire/ -- ViratechCorp. (OTC: VIRA), the first open source biotech research social networkplatform, announced today the addition of Edmund Freund, MD to itsAdvisory Committee.Edmund Freund, MD, completed his undergraduate and medicaleducation at the University of Iowa. He completed a family practice residency atSan Joaquin General Hospital in Stockton, which is affiliated with UC Davis, in1981. He began a family practice inLodi with Vinewood Family Practice in 1981. Dr. Greund has also held administrative roles at Lodi MemorialHospital. In 2002 he became MedicalDirector of Lodi Memorial Hospital Emergency Medicine Department. In 2009 he returnedto family practice with Lodi Memorial Community Clinics. “With Dr. Freund’s leadership roles, and his clinicalexperience in Primary Care and Emergency Medicine over the last 30 years, heunderstands the need for new ways to reduce health care costs and improvequality of care,” states Dr. Kevin Buckman, the CEO of Viratech. Dr. Buckman adds, “He will be a great assetto the Advisory Board of Viratech as we implement the use of our social networkplatforms, research, and other resources that are needed in ER and primary carehealth. He also understands theimportance of early disease detection,” He adds, “Working in ER and Primary Care is the best way to see a broadrange of medical problems, and we look forward to Dr. Freund’s administrativeand practical experience to our Board.”About Viratech Corp.Based in Stockton, California, Viratech Corp. has created anopen source biotech research and development platform, Viratech has created aunique platform leveraging the utility of social collaboration, which willallow cancer research the opportunity for the first time to become opensourced. This is accomplished byallowing our development partners the ability to protect, promote and producetheir research in unified online collaboration hubs known as micro socialnetworks. Viratech’s open source platform has integrated several intellectualproperty tools which, by leveraging our social collaboration network, can giveour development partners a new intellectual property mechanism, which will helpin addressing the protection of Intellectual Property, promotion throughcollaboration in our protected open source platform, and commercial developmentof the products achieved through collaborative research.Using this platform, Viratech members can protect theirintellectual property, then use Viratech’s micro social network as a utility topromote and crowdfund the research and development to produce the newtechnology. Forward-Looking Statements:This press release includes forward-looking statementsconcerning the future performance of our business, its operations and itsfinancial performance and condition, and also includes selected operatingresults presented without the context of accompanying financial results. Theseforward-looking statements include, among others, statements with respect toour objectives and strategies to achieve those objectives, as well asstatements with respect to our beliefs, plans, expectations, anticipations,estimates or intentions. These forward-looking statements are based on ourcurrent expectations. We caution that all forward-looking information isinherently uncertain and actual results may differ materially from theassumptions, estimates or expectations reflected or contained in theforward-looking information, and that actual future performance will beaffected by a number of factors, including economic conditions, technologicalchange, regulatory change and competitive factors, many of which are beyond ourcontrol. Therefore, future events and results may vary significantly from whatwe currently foresee. We are under no obligation (and we expressly disclaim anysuch obligation) to update or alter the forward-looking statements whether as aresult of new information, future events or otherwise. Contact: Kevin Buckman MDViratech, Corp.http://viratech.orgEmail Contact: info@viratech.org
test123 kjk
